Infectious Diseases Now,
Год журнала:
2025,
Номер
55(2), С. 105040 - 105040
Опубликована: Фев. 16, 2025
Positive
cardiovascular
and
renal
outcomes
associated
with
the
sodium-glucose
cotransporter
2
inhibitor
(SGLT2i)
use
are
attributed
to
their
anti-inflammatory
properties.
Persistent
immune
activation
accounts
for
part
of
elevated
risk
people
living
HIV
(PWH),
but
SGLT2i
impact
on
this
population
has
been
poorly
described.
All
PWH
a
history
treatment
from
May
2020
April
2023
receiving
care
at
Pitié-Salpêtrière
Hospital
(Paris,
France)
available
pre-
post-treatment
blood
samples
were
included.
Clinical
biological
data
extracted
medical
records,
metabolic
biomarkers
cryopreserved
plasma
samples.
Most
20
patients
men
(75
%),
median
[IQR]
age
59
years
[55;68],
antiretroviral
therapy
21.5
[15.3;26.5].
had
type
diabetes
(95
chronic
kidney
disease
(90
dyslipidemia
(80
hypertension
%).
was
weight
loss
3
kg,
an
increase
in
hematocrit,
decreased
AST
levels.
LDL,
HDL,
oxLDL,
Lp-PLA2
levels
unaffected.
inflammasome
inhibition
circulating
IL-1β
IL-8.
We
also
observed
decrease
cytokines
recruitment
monocytes-macrophages
MCP-1,
MIP-1α,
MIP-1β,
Eotaxin,
RANTES,
IL-8,
positive
feedback,
IL-13/IL-4.
Decreased
IL-6,
CRP,
sCD14
not
significant.
significant
innate
immunity
PWH,
monocyte-macrophage
activation.
Current Pharmaceutical Design,
Год журнала:
2024,
Номер
30(13), С. 969 - 974
Опубликована: Март 29, 2024
Abstract:
In
metabolic
syndrome
and
diabetes,
compromised
mitochondrial
function
emerges
as
a
critical
driver
of
cardiovascular
disease,
fueling
its
development
persistence,
culminating
in
cardiac
remodeling
adverse
events.
this
context,
angiotensin
II
-
the
main
interlocutor
renin-angiotensin-aldosterone
system
promotes
local
systemic
oxidative
inflammatory
processes.
To
highlight,
low
activity/expression
proteins
called
sirtuins
negatively
participates
these
processes,
allowing
more
significant
imbalance,
which
impacts
cellular
tissue
responses,
causing
damage,
inflammation,
vascular
remodeling.
The
reduction
energy
production
mitochondria
has
been
widely
described
element
all
types
disorders.
Additionally,
high
sirtuin
levels
AMPK
signaling
stimulate
hypoxia-inducible
factor
1
beta
promote
ketonemia.
Consequently,
enhanced
autophagy
mitophagy
advance
through
cells,
sweeping
away
debris
silencing
orchestra
stress
ultimately
protecting
vulnerable
from
damage.
highlight
particular
interest,
SGLT2
inhibitors
(SGLT2i)
profoundly
influence
mechanisms.
Randomized
clinical
trials
have
evidenced
compelling
picture
SGLT2i
emerging
game-changers,
wielding
their
power
to
demonstrably
improve
slash
rates
renal
Furthermore,
driven
by
recent
evidence,
emerge
supermolecules,
exerting
beneficial
actions
increase
efficiency,
alleviate
stress,
curb
severe
inflammation.
Its
strengthen
tissues
create
resilient
defense
against
disease.
conclusion,
like
treasure
chest
brimming
with
untold
riches,
on
holds
potential
for
health.
Unlocking
secrets,
map
guiding
adventurers
hidden
promises
pave
way
even
potent
therapeutic
strategies.
Medicina,
Год журнала:
2025,
Номер
61(2), С. 202 - 202
Опубликована: Янв. 23, 2025
Background:
Sodium–glucose
co-transporter-2
(SGLT2)
inhibitors
have
emerged
as
vital
medications
for
the
management
of
type
2
diabetes
mellitus
(T2DM).
Numerous
studies
highlighted
cardioprotective
and
renal
protective
benefits
SGLT2
inhibitors.
Consequently,
it
is
essential
to
assess
their
efficacy
safety
in
patients
with
chronic
diseases.
Method:
We
conducted
a
systematic
review
meta-analysis
randomized
controlled
trials
(RCTs)
evaluating
effects
on
major
cardiovascular
outcomes
T2DM,
heart
failure
(HF),
kidney
disease
(CKD).
searched
PubMed,
Cochrane,
Embase
databases
published
between
30
September
2021
17
May
2023.
The
primary
interest
included
nonfatal
myocardial
infarction
(MI),
hospitalization
(HHF),
death,
stroke.
assessed
were
hypoglycemia,
urinary
tract
infections
(UTIs),
acute
injury
(AKI).
Result:
identified
13
RCTs
involving
90,413
participants.
In
significantly
reduced
risk
MI
by
12%
(hazard
ratio
[HR]
=
0.88,
95%
confidence
interval
[CI]:
0.78–0.98),
HHF
33%
(HR
0.67,
CI:
0.62–0.74),
cardiac
death
15%
0.95,
0.80–1.13).
However,
they
did
not
reduce
stroke
0.85,
0.75–0.95).
HF,
28%
0.72,
0.66–0.77)
0.80–0.96).
For
CKD,
35%
0.65,
0.55–0.76)
16%
0.84,
0.73–0.96).
Regarding
outcomes,
increase
hypoglycemia
or
nor
(UTIs)
HF
(AKI)
HF.
UTIs
8%
(risk
[RR]
1.08,
1.01–1.16)
T2DM
AKI
22%
(RR
0.78,
0.67–0.89)
19%
0.81,
0.69–0.97)
respectively.
Conclusions:
demonstrated
significant
improvement
CKD
while
also
maintaining
favorable
profile.
These
findings
advocate
broader
application
diseases,
particularly
reducing
incidence
MI,
HHF,
death.
Further
research
optimize
use
across
diverse
patient
populations
stages
disease.
Infectious Diseases Now,
Год журнала:
2025,
Номер
55(2), С. 105040 - 105040
Опубликована: Фев. 16, 2025
Positive
cardiovascular
and
renal
outcomes
associated
with
the
sodium-glucose
cotransporter
2
inhibitor
(SGLT2i)
use
are
attributed
to
their
anti-inflammatory
properties.
Persistent
immune
activation
accounts
for
part
of
elevated
risk
people
living
HIV
(PWH),
but
SGLT2i
impact
on
this
population
has
been
poorly
described.
All
PWH
a
history
treatment
from
May
2020
April
2023
receiving
care
at
Pitié-Salpêtrière
Hospital
(Paris,
France)
available
pre-
post-treatment
blood
samples
were
included.
Clinical
biological
data
extracted
medical
records,
metabolic
biomarkers
cryopreserved
plasma
samples.
Most
20
patients
men
(75
%),
median
[IQR]
age
59
years
[55;68],
antiretroviral
therapy
21.5
[15.3;26.5].
had
type
diabetes
(95
chronic
kidney
disease
(90
dyslipidemia
(80
hypertension
%).
was
weight
loss
3
kg,
an
increase
in
hematocrit,
decreased
AST
levels.
LDL,
HDL,
oxLDL,
Lp-PLA2
levels
unaffected.
inflammasome
inhibition
circulating
IL-1β
IL-8.
We
also
observed
decrease
cytokines
recruitment
monocytes-macrophages
MCP-1,
MIP-1α,
MIP-1β,
Eotaxin,
RANTES,
IL-8,
positive
feedback,
IL-13/IL-4.
Decreased
IL-6,
CRP,
sCD14
not
significant.
significant
innate
immunity
PWH,
monocyte-macrophage
activation.
